Grifols (GIFLF) Non-Current Assets (2009 - 2025)
Grifols' (GIFLF) quarterly Non-Current Assets came in at $17.0 billion in Q4 2025, up 1.71% on a YoY basis from $16.8 billion in Q4 2024, and up 1.71% quarter-over-quarter from $16.8 billion in Q4 2024.
Analysis
Grifols (GIFLF) Non-Current Assets (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Non-Current Assets for 17 consecutive years, with $17.0 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 1.71% year-over-year to $17.0 billion; the trailing twelve-month figure through Dec 2025 stood at $17.0 billion (up 1.71% YoY), and the FY2025 full-year result was $16.5 billion, down 1.28% from the prior year.
- Non-Current Assets grew to $17.0 billion in Q4 2025 per GIFLF's latest filing, from $16.8 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $17.0 billion in Q4 2025 and bottomed at $15.7 billion in Q4 2021.
- Historically, Non-Current Assets has averaged $16.5 billion across 5 years, with a median of $16.8 billion in 2024.
- The sharpest annual moves came in 2021 and 2023: Non-Current Assets grew 8.73% in 2021, then slipped 5.24% in 2023.
- Over 5 years, Non-Current Assets stood at $15.7 billion in 2021, then gained by 7.48% to $16.9 billion in 2022, then decreased by 5.24% to $16.0 billion in 2023, then grew by 4.77% to $16.8 billion in 2024, then increased by 1.71% to $17.0 billion in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $17.0 billion, $16.8 billion, and $16.0 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 17.04 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 17.04 Bn |
| Dec 31, 2024 | 16.75 Bn |
| Dec 31, 2023 | 15.99 Bn |
| Dec 31, 2022 | 16.87 Bn |
| Dec 31, 2021 | 15.70 Bn |
| Dec 31, 2020 | 14.44 Bn |
| Sep 30, 2020 | 14.02 Bn |
| Mar 31, 2020 | 13.50 Bn |
| Dec 31, 2019 | 11.27 Bn |
| Sep 30, 2019 | 11.55 Bn |
| Mar 31, 2019 | 11.25 Bn |
| Dec 31, 2018 | 10.27 Bn |
| Sep 30, 2018 | 10.18 Bn |
| Jun 30, 2018 | 10.13 Bn |
| Mar 31, 2018 | 12.80 Bn |
| Dec 31, 2017 | 9.39 Bn |
| Jun 30, 2017 | 9.09 Bn |
| Dec 31, 2016 | 7.57 Bn |
| Sep 30, 2016 | 7.38 Bn |
| Jun 30, 2016 | 7.48 Bn |